Sparger Ellen E, Chang Hong, Chin Ning, Rebhun Robert B, Withers Sita S, Kieu Hung, Canter Robert J, Monjazeb Arta M, Kent Michael S
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
Center for Companion Animal Health, Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
Front Vet Sci. 2021 Dec 2;8:772932. doi: 10.3389/fvets.2021.772932. eCollection 2021.
Investigation of canine T cell immunophenotypes in canine melanomas as prognostic biomarkers for disease progression or predictive biomarkers for targeted immunotherapeutics remains in preliminary stages. We aimed to examine T cell phenotypes and function in peripheral blood mononuclear cells (PBMC) and baseline tumor samples by flow cytometry, and to compare patient ( = 11-20) T cell phenotypes with healthy controls dogs ( = 10-20). CD3, CD4, CD8, CD25, FoxP3, Ki67, granzyme B, and interferon-γ (IFN-γ) were used to classify T cell subsets in resting and mitogen stimulated PBMCs. In a separate patient cohort ( = 11), T cells were classified using CD3, CD4, CD8, FoxP3, and granzyme B in paired PBMC and single cell suspensions of tumor samples. Analysis of flow cytometric data of individual T cell phenotypes in PBMC revealed specific T cell phenotypes including FoxP3+ and CD25+FoxP3- populations that distinguished patients from healthy controls. Frequencies of IFN-γ+ cells after ConA stimulation identified two different patient phenotypic responses, including a normal/exaggerated IFN-γ response and a lower response suggesting dysfunction. Principle component analysis of selected T cell immunophenotypes also distinguished patients and controls for T cell phenotype and revealed a clustering of patients based on metastasis detected at diagnosis. Findings supported the overall hypothesis that canine melanoma patients display a T cell immunophenotype profile that is unique from healthy pet dogs and will guide future studies designed with larger patient cohorts necessary to further characterize prognostic T cell immunophenotypes.
将犬黑色素瘤中的犬T细胞免疫表型作为疾病进展的预后生物标志物或靶向免疫治疗的预测生物标志物的研究仍处于初步阶段。我们旨在通过流式细胞术检测外周血单个核细胞(PBMC)和基线肿瘤样本中的T细胞表型和功能,并将患者(n = 11 - 20)的T细胞表型与健康对照犬(n = 10 - 20)进行比较。使用CD3、CD4、CD8、CD25、FoxP3、Ki67、颗粒酶B和干扰素-γ(IFN-γ)对静息和丝裂原刺激的PBMC中的T细胞亚群进行分类。在一个单独的患者队列(n = 11)中,使用CD3、CD4、CD8、FoxP3和颗粒酶B对配对的PBMC和肿瘤样本的单细胞悬液中的T细胞进行分类。对PBMC中单个T细胞表型的流式细胞术数据分析揭示了特定的T细胞表型,包括将患者与健康对照区分开来的FoxP3 +和CD25 + FoxP3 -群体。ConA刺激后IFN-γ +细胞的频率确定了两种不同的患者表型反应,包括正常/过度的IFN-γ反应和提示功能障碍的较低反应。对选定的T细胞免疫表型进行主成分分析也区分了患者和对照的T细胞表型,并揭示了基于诊断时检测到的转移的患者聚类。研究结果支持了总体假设,即犬黑色素瘤患者表现出与健康宠物狗不同的T细胞免疫表型谱,并将指导未来使用更大患者队列进行的研究,以进一步表征预后T细胞免疫表型。